Cardiovascular Mortality following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08

Efstathiou, Jason A.; Paulus, Rebecca; Smith, Michael; Jones, Clifford; Leibenhaut, Mark H.; Husain, Siraj; Rotman, Marvin; Souhami, L.; Sandler, Howard M.; Shipley, William U.

doi:10.1016/j.ijrobp.2011.06.084

Cited by 2 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that longer duration of adjuvant GnRHa therapy did not appear to increase CV mortality. Other studies and a recent meta-analysis have reported similar findings [4,16,19,25].…”

Section: Discussionsupporting

confidence: 67%

“…Data are contradictory and based on retrospective analysis of randomized trials (RTOG 9202 [6,22], RTOG8531 [3], RTOG8610 [4], RTOG 9408 [25,27], EORTC22863 [2], TROG9601 [5]). The panel concluded that there is an association-albeit not a direct one-between the use of ADT and a greater risk of cardiac events in patients with previous severe CV comorbidity.…”

Section: Resultsmentioning

confidence: 99%

“…Is there a relationship between duration of ADT and greater risk of CV mortality? At present, the available evidence does not allow us to prove a relationship between CV mortality and duration of ADT in the context of adjuvant RT [12,22,25]. Some data suggest that more caution should be taken in patients with severe CV risk factors and age [70 years [17,18] …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

et al. 2014

View full text Add to dashboard Cite

show abstract

A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer

Wolff

Ryder

Bossi

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

Based on this systematic review, there is no strong evidence to support one therapy over another as EBRT, BT and RP can all be considered as effective monotherapies for localised disease with EBRT also effective for post-operative management. All treatments have unique adverse events profiles. Further large, robust RCTs which report treatment-specific and treatment combination-specific outcomes in defined prostate cancer risk groups following established reporting standards are needed. These will strengthen the evidence base for newer technologies, help reinforce current consensus guidelines and establish greater standardisation across practices.

show abstract

Cardiovascular Mortality following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08

Cited by 2 publications

References 16 publications

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer

Contact Info

Product

Resources

About